MXPA03008999A - Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp. - Google Patents

Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.

Info

Publication number
MXPA03008999A
MXPA03008999A MXPA03008999A MXPA03008999A MXPA03008999A MX PA03008999 A MXPA03008999 A MX PA03008999A MX PA03008999 A MXPA03008999 A MX PA03008999A MX PA03008999 A MXPA03008999 A MX PA03008999A MX PA03008999 A MXPA03008999 A MX PA03008999A
Authority
MX
Mexico
Prior art keywords
drug
alpha
methylpropiono
fluorophenylsulphonyl
toluidide
Prior art date
Application number
MXPA03008999A
Other languages
English (en)
Inventor
Julie Kay Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03008999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03008999A publication Critical patent/MXPA03008999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA03008999A 2001-04-02 2002-03-27 Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp. MXPA03008999A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number Publication Date
MXPA03008999A true MXPA03008999A (es) 2004-02-12

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008999A MXPA03008999A (es) 2001-04-02 2002-03-27 Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.

Country Status (21)

Country Link
US (1) US20040138299A1 (es)
EP (1) EP1381358B1 (es)
JP (1) JP2004525164A (es)
KR (1) KR20030087048A (es)
CN (1) CN1536993A (es)
AT (1) ATE324886T1 (es)
BR (1) BR0208421A (es)
CA (1) CA2443040A1 (es)
CZ (1) CZ20032647A3 (es)
DE (1) DE60211139T2 (es)
EE (1) EE200300476A (es)
ES (1) ES2261655T3 (es)
HU (1) HUP0303454A3 (es)
IL (1) IL157955A0 (es)
IS (1) IS6970A (es)
MX (1) MXPA03008999A (es)
NO (1) NO20034386L (es)
NZ (1) NZ528284A (es)
PL (1) PL365330A1 (es)
SK (1) SK12032003A3 (es)
WO (1) WO2002080902A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439366A1 (en) * 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
MX2007006373A (es) * 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
WO2007014393A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
PT2278960T (pt) 2008-03-17 2017-03-09 Actelion Pharmaceuticals Ltd Regime de dosagem para um agonista seletivo do recetor s1p1
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
BR112013013028B1 (pt) 2011-01-13 2021-02-09 Bio-Pharm Solutions Co., Ltd processo para a preparação de derivados de carbamato de fenila e composto
KR20140113919A (ko) 2011-12-27 2014-09-25 (주)바이오팜솔루션즈 다발성 경화증의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN106456566B (zh) * 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
ES2839128T3 (es) 2014-12-05 2021-07-05 Aragon Pharmaceuticals Inc Composiciones anticancerosas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508125A (ja) * 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
HUP0303454A2 (hu) 2004-01-28
PL365330A1 (en) 2004-12-27
ES2261655T3 (es) 2006-11-16
IS6970A (is) 2003-09-29
EP1381358A1 (en) 2004-01-21
HUP0303454A3 (en) 2005-12-28
ATE324886T1 (de) 2006-06-15
NO20034386D0 (no) 2003-10-01
NO20034386L (no) 2003-11-28
DE60211139T2 (de) 2007-03-01
DE60211139D1 (de) 2006-06-08
BR0208421A (pt) 2004-03-30
IL157955A0 (en) 2004-03-28
CN1536993A (zh) 2004-10-13
SK12032003A3 (sk) 2004-03-02
WO2002080902A1 (en) 2002-10-17
EP1381358B1 (en) 2006-05-03
JP2004525164A (ja) 2004-08-19
CA2443040A1 (en) 2002-10-17
EE200300476A (et) 2003-12-15
US20040138299A1 (en) 2004-07-15
CZ20032647A3 (cs) 2004-09-15
NZ528284A (en) 2005-04-29
KR20030087048A (ko) 2003-11-12

Similar Documents

Publication Publication Date Title
IL157955A0 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
UY27186A1 (es) Formulación farmacéutica
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
DK1471892T3 (da) Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
MXPA04003520A (es) Formulacion farmaceutica que comprende (r)-bicalutamida.
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
TW200505452A (en) Chemical compounds
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
SE0103839D0 (sv) Pharmaceutical formulation & product
WO2002028424A3 (en) Kyberdrug as autovaccines with immune-regulating effects
SE0103838D0 (sv) Pharmaceutical formulation & product
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
CA2329665A1 (en) Treatment of depression and pharmaceutical preparations therefor
RU2003132064A (ru) Твердая фармацевтическая композиция, содержащая 4-циано-трифтор-3-(4-фторфенилсуфонил)-2-гидрокси-2-метилпропионо-м толуидид и pvp
BR0207572A (pt) Formulação farmacêutica, dose diária farmacêutica de bicalutamida administrável através das mucosas a um paciente, dispersão sólida de um polìmero entérico, e, uso de um polìmero entérico